Perindopril

Perindopril
Clinical data
Trade names	Coversyl, Coversum, Aceon
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
ATC code	C09AA04 (WHO) ; C09BA04 (WHO) (with diuretics); C09BB04 (WHO) (with amlodipine);
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	24%
Protein binding	20%
Metabolism	Kidney
Elimination half-life	1–17 hours for perindoprilat (active metabolite)
Identifiers
	IUPAC name (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid;
CAS Number	82834-16-0 ;
PubChem CID	107807;
IUPHAR/BPS	6367;
DrugBank	DB00790 ;
ChemSpider	96956 ;
UNII	Y5GMK36KGY;
KEGG	D03753 ;
ChEBI	CHEBI:8024 ;
ChEMBL	ChEMBL1581 ;
CompTox Dashboard (EPA)	DTXSID6023440 ;
ECHA InfoCard	100.120.843
Chemical and physical data
Formula	C19H32N2O5
Molar mass	368.474 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@H]12)C)CCC;
	InChI InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1 ; Key:IPVQLZZIHOAWMC-QXKUPLGCSA-N ;
	(what is this?) (verify)

Perindopril is a medication used to treat high blood pressure, heart failure, or stable coronary artery disease.^[2]

As a long-acting ACE inhibitor, it works by relaxing blood vessels and decreasing blood volume. As a prodrug, perindopril is hydrolyzed in the liver to its active metabolite, perindoprilat. It was patented in 1980 and approved for medical use in 1988.^[3]

Perindopril is taken in the form of perindopril arginine (with arginine, trade names include Coversyl, Coversum) or perindopril erbumine (with erbumine (tert-Butylamine), trade name Aceon). Both forms are therapeutically equivalent and interchangeable,^[4] but the dose prescribed to achieve the same effect differs between the two forms. It is also often combined with another medication, sometimes in the same tablet (see § Combination therapy below).

^ "Regulatory Decision Summary for APO-Perindopril Arginine". Health Canada. 23 October 2014.
^ "Consumer Medicine Information, GenRx Perindopril" (PDF). Clinical Resources, Medicine information for health professionals. Royal Australian College of General Practitioners. Archived from the original (PDF) on 2007-09-01.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 9783527607495.
^ "PBS For Health Professionals". Pharmaceutical Benefits Scheme. Australian Government Department of Health and Ageing. 2008. Archived from the original on 2008-10-30. Retrieved 2008-09-04.

[1] "Regulatory Decision Summary for APO-Perindopril Arginine". Health Canada. 23 October 2014.

[2] "Consumer Medicine Information, GenRx Perindopril" (PDF). Clinical Resources, Medicine information for health professionals. Royal Australian College of General Practitioners. Archived from the original (PDF) on 2007-09-01.

[Fisher_2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 9783527607495.

[4] "PBS For Health Professionals". Pharmaceutical Benefits Scheme. Australian Government Department of Health and Ageing. 2008. Archived from the original on 2008-10-30. Retrieved 2008-09-04.

[1]

[2]

[3]

[4]